Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The ‘real-world’ patient population of metastatic melanoma is not fully represented in clinical trials investigating checkpoint inhibitors. We described therapy discontinuation in an unselected population-based cohort of adults with metastatic melanoma who started therapy with pembrolizumab, nivolumab, or nivolumab/ipilimumab from January 2015 to August 2017. Therapy discontinuation was defined as a gap between doses beyond 120 days, and/or initiation of another cancer therapy. We estimated drug-specific rate ratios for therapy discontinuation adjusted for age, sex, comorbidities, health care use, and past cancer therapies. We included 876 metastatic melanoma patients initiating pembrolizumab (44.3%), nivolumab/ipilimumab (31.2%), and nivolumab (24.5%). At 12 months of follow-up, the probabilities of therapy discontinuation were 49.9% (95% confidence interval, CI 43.6–56.5) for pembrolizumab, 58.8% (95% CI 50.5–67.3) for nivolumab, and 59.2% (95% CI 51.7–66.8) for nivolumab/ipilimumab. Stratified analyses based on prior cancer therapy, brain metastases at baseline, and sex showed similar trends. In multivariable analyses, compared with pembrolizumab, patients starting nivolumab (rate ratio 1.38, 95% CI 1.08–1.77) or nivolumab/ipilimumab (rate ratio 1.30, 95% CI 1.02–1.65) were more likely to discontinue therapy. Our findings indicate frequent discontinuations of checkpoint inhibitors at one year. The lower discontinuation associated with pembrolizumab should be confirmed in further studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the more frequent severe immune-related adverse effects experienced with CICB when compared to anti-PD-1 or anti-PD-L1 monotherapy 8 .”
From A gut microbial signature for combination immune checkpoint blockade across cancer types (2024) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Sex differences in immune responses
Klein, S. L., & Flanagan, K. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.90 · Cited by 6,370
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Targeted agents and immunotherapies: optimizing outcomes in melanoma
Luke, J. J., Flaherty, K. T., Ribas, A., & Long, G. V. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.43 · Cited by 1,254
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Coit, D. G., Thompson, J. A., Albertini, M. R., Barker, C., Carson, W. E., Contreras, C., Daniels, G. A., DiMaio, D., Fields, R. C., Fleming, M. D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0018 · Cited by 436
Villadolid, J. J., & Amin, A. (2015) · PubMed · doi:10.3978/j.issn.2218-6751.2015.06.06 · Cited by 409
Jansen, Y. J. L., Rozeman, E. A., Mason, R., Goldinger, S. M., Geukes Foppen, M. H., Hoejberg, L., Schmidt, H., van Thienen, J. V., Haanen, J. B. A. G., Tiainen, L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz110 · Cited by 226
Cited by
A gut microbial signature for combination immune checkpoint blockade across cancer types
Gunjur, A., Shao, Y., Rozday, T., Klein, O., Mu, A., Haak, B. W., Markman, B., Kee, D., Carlino, M. S., Underhill, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02823-z · Cited by 165
The lung, the niche, and the microbe: Exploring the lung microbiome in cancer and immunity
Huynh, M., Crane, M. J., & Jamieson, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1094110 · Cited by 25
Yiu, C. H., Menzies, A. M., & Lu, C. Y. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01164-2 · Cited by 11
Kelly, D., Rose, A. A. N., Muniz, T. P., Hogg, D., Butler, M. O., Saibil, S. D., King, I. F. G., Kamil, Z. S., Ghazarian, D., Ross, K., et al. (2021) · Cancers · doi:10.3390/cancers13143640 · Cited by 11
“In cutaneous melanoma, it is well established that responses can be maintained for an extended period of time after ICI treatment discontinuation [40].”
BackgroundYiu, C. H., Lee, A., & Lu, C. Y. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01181-1 · Cited by 6
“Consistent with previous studies, treatment discontinuation was assessed for nivolumab only, as ipilimumab is administered concurrently for up to four doses during the induction phase, followed by nivolumab maintenance mono-therapy [32].”
Metadata
- Authors
- Machado, M. A. D. Á., de Moura, C. S., Chan, K., Curtis, J. R., Hudson, M., Abrahamowicz, M., Jamal, R., Pilote, L., & Bernatsky, S.
- Affiliations
- McGill University (CA)
- Sunnybrook Health Science Centre (CA)
- University of Alabama at Birmingham (US)
- Jewish General Hospital (CA)
- Centre Hospitalier de l’Université de Montréal (CA)
- Corresponding author
- Bernatsky, Sasha
- ORCID
- Venue
- Scientific Reports
- Published
- 2020-09-03
- Volume
- 10
- Issue
- 1
- Pages
- 14607-14607
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC7471311
- OpenAlex
- W3082399821
- Cited by
- 14
- References
- 24
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 2 · 2023: 2 · 2022: 1 · 2021: 1
- FWCI
- 0.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- metastatic melanoma, immune checkpoint inhibitors, treatment discontinuation, pembrolizumab, nivolumab, real-world evidence, immunotherapy, brain metastases, sex differences
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Nivolumab, Immune Checkpoint Inhibitors, Aged, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Withholding Treatment, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. https://app.cochat.ai/papers/10.1038/s41598-020-71788-z
- The paper
- Machado, M. A. D. Á., de Moura, C. S., Chan, K., Curtis, J. R., Hudson, M., Abrahamowicz, M., Jamal, R., Pilote, L., & Bernatsky, S. (2020). Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients. Scientific Reports. https://doi.org/10.1038/s41598-020-71788-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
